2020 Top 10 Innovations

From a rapid molecular test for COVID-19 to tools that can characterize the antibodies produced in the plasma of patients recovering from the disease, this year’s winners reflect the research community’s shared focus in a challenging year.

The Scientist Staff
Dec 1, 2020

 ABOVE: © The Scientist Staff

We recognize the vintage saw: necessity is the mom of invention. Well, 2020 has proven us that a international pandemic is one extreme mom. Typically, our Top 10 Innovations opposition specializes in laboratory technology, gear designed to plumb the mysteries of simple biology. But as biologists became their attractions to expertise SARS-CoV-2, the innovation panorama modified accordingly, with new gear evolved and present technology bent to deal with the pandemic. So this yr at The Scientist, our annual contest carries innovations aimed toward expertise and in the long run fixing the COVID-19 problem.

Among our impartial judges’ alternatives for 2020’s Top 10 Innovations had been middle laboratory technologyinclusive of a single-mobileular proteome analyzer and a computer gene synthesizer—along pandemic-targeted merchandise, which includes a speedy COVID-19 test, a device that could seize antibody profiles from the blood plasma of recuperating coronavirus patients, and a platform for characterizing glycans withinside the spike protein that studs the floor of SARS-CoV-2. The opposition amongst stellar submissions changed into so steep that this yr’s Top 10 truely consists of 12 merchandise, way to multiple ties.

As tough as 2020 has been for all of us, this tumultuous yr has given delivery to promising merchandise and procedures for elucidating the complicated global of biology. And even extra than that, 2020 has proven that the medical community, whilst confronted with a shared problem, can upward thrust to the undertaking and are available collectively to refocus, research, and innovate. Here, The Scientist gives the gear and technology that make up this yr’s Top 10 Innovations.

AbCellera Celium


In overdue March, biotech company AbCellera hosted a name with forty researchers to study the records they’d gathered on capability antibodies in opposition to SARS-CoV-2. Using AbCellera’s high-throughput microfluidics and single-mobileular evaluation equipment to probe samples of COVID-19 sufferers, the company’s crew had deciphered the genetic sequences encoding masses of antibodies that could deal with the disease. Sifting via all of that records through hand turned into tedious, though, so the crew fed it into Celium, a records visualization device that intersects extra than 1,000,000 first rate records factors for the ones antibodies to expose which of them would possibly paintings first-class in sufferers as a capability therapy. In actual time, at the name, the researchers used Celium to probe the ones relationships and domestic in at the LY-CoV555 antibody that, months later, entered medical trials as a probable COVID-19 treatment, says Maia Smith, lead of records visualization at AbCellera and author of Celium. “I suppose that form of says it all.”

Before Celium got here available in the marketplace in 2017, scientists running with AbCellera to discover antibodies could get lower back complicated spreadsheets of records that had been tough to navigate, and it turned into difficult to recognize wherein to start, Smith says. Using Celium, records are provided in a visible layout and the device “facilitates you perceive the proper molecule to your needs,” Fernando Corrêa, a protein engineer at Kodiak Sciences in Palo Alto, California tells The Scientist. He’s partnered with AbCellera to perceive antibodies to deal with retinal diseases, and says the company’s package deal of microfluidics, single-mobileular evaluation, and records visualization device “streamlines the procedure of antibody discovery in a user-pleasant manner.”

KAMDAR: “AbCellera’s reaction to the pandemic underscores the actual energy of the Celium platform on the intersection of biology and AI to make new antibody discoveries at a blazing speed.”

Abbott ID NOW COVID-19 Test


Since 2014, Abbott’s ID NOW machine has helped physicians discover influenzas A and B, strep A, breathing syncytial virus (RSV), and maximum lately SARS-CoV-2, in much less than 15 mins. The toaster-length tool works with the aid of using heating nasal samples in an acidic answer that cracks open the envelope of theviruses, exposing their RNA, which ID NOW amplifies at a regular temperature in preference to the heating and cooling cycles that PCR machines use. Gaining emergency authorization from americaA Food and Drug Administration in overdue March, the COVID-19 ID NOW take a look at changed into one of the first assessments available to americaA public.

Norman Moore, Abbott’s director of medical affairs for infectious diseases, says the take a look at’s brief turnaround time is important to preventing viral spread. “You’re the maximum infectious early on—and if we don’t have that bring about that well timed fashion, what does it assist if a molecular take a look at comes lower back weeks later?” he tells The Scientist.

With extra than 23,000 ID NOW gadgets in use withinside the US, in particular in pressing care clinics and pharmacies, Moore says his crew is growing assessments well matched with the platform for different infectious diseases, including sexually transmitted infections.

J.D. Zipkin, leader clinical officer of GoHealth Urgent Care, which partnered with San Francisco International Airport to manage the ID NOW COVID-19 take a look at to travelers, calls the take a look at a sport changer. “[Abbott] took a platform that’s already actually precise at detecting very unique disorder states and carried out it to the most important pandemic want that we’ve on this country,” he says.

The ID NOW platform costs $4,500 and every COVID-19 take a look at costs $40.

CRUICKSHANK-QUINN: “The cappotential to obtain COVID-19 take a look at effects from a throat or nasal swab in below 15 mins can offer hospitals, schools, or another organization with the cappotential to fast take a look at individuals to decide individuals who might want to self-isolate at home. Since it’s miles lightweight and transportable it could be used withinside the discipline and at cellular webweb sites like drive-through checking out locations.”

BioLegend TotalSeq-C Human Universal Cocktail v1.0

In 2017, researchers from the New York Genome Center published a brand new method referred to as CITE-seq that permits scientists to evaluate proteins in character cells on the equal time they’re doing unmarried-cellular transcriptomics. CITE-seq works with the aid of using linking antibodies with oligonucleotides which could finally be sequenced to show whether or not goal proteins have been gift and joined to their corresponding antibodies. Life technological know-how organisation BioLegend certified CITE-seq and evolved the TotalSeqTM-C Human Universal Cocktail v1.0, a group of one hundred thirty oligo-related antibodies for big screening of the cellular-floor proteins of character cells, to be used on a unmarried-cellular sequencing platform from 10X Genomics.


In assessment to proteomics methods primarily based totally on visible evaluation of tagged proteins, “there’s no theoretical restriction anymore as to what number of proteins you may [screen for],” says BioLegend’s Head of Proteogenomics Kristopher “Kit” Nazor, including that the organisation is already running to enlarge the wide variety of antibodies protected withinside the cocktail. “That will increase the possibility for independent discovery massively.”

“It’s groundbreaking in lots of approaches,” says immunologist and genomicist Alexandra-Chloé Villani of Massachusetts General Hospital, Harvard Medical School, and the Broad Institute of MIT and Harvard University. Like many researchers, Villani, who’s one of the coordinators of the immune cellular phase of the Human Cell Atlas, pivoted this 12 months to analyzing COVID-19. She has already used BioLegend’s cocktail, released in early August at a rate of $5,350 for 5 unmarried-use vials, to research blood samples from almost three hundred sufferers who examined nice for SARS-CoV-2.

“When you’ve got got floor protein and RNA withinside the equal cellular, it sincerely allows us to derive a greater granular definition of the immune cells concerned” in reaction to contamination, says Villani. “I definitely realize a whole lot of colleagues throughout the US and Europe which have used this equal panel to research their COVID cohorts . . . because of this that we’ll be capable of integrate all of our facts and compare. And that’s incredible.”

MEAGHER: “This is a sincerely best merging of subsequent-gen sequencing as a virtual readout for series barcodes and unmarried-cellular barcoding generation to allow unmarried-cellular quantitative proteomics.”

Seven Bridges GRAF


The launch of the human reference genome in 2013 became a incredible soar ahead for biology, however as a ways as definitely representing humanity, it fell pretty brief. Our genomes are rife with versions now no longer gift withinside the reference genome, which became constructed from a small sampling of individuals, in general of European descent. To account for human genetic diversity, bioinformatics company Seven Bridges has evolved a genomic evaluation platform referred to as GRAF that tries to encompass all viable iterations of genetic sequences at any given locus. The ensuing GRAF/Pan Genome Reference is a graph of the acknowledged versions at specific factors withinside the genome, in place of a linear reference series. When genomes are aligned to the GRAF reference, any deletions, insertions, unmarried nucleotide polymorphisms, or different versions are consequently now no longer neglected as they is probably while aligned to the linear reference genome.

With the aim of boosting the presence of underrepresented companies in genomic studies, Seven Bridges introduced in June that get admission to to its GRAF Germline Variant Detection Workflow and GRAF/Pan Genome Reference could be loose to educational researchers. “This is the primary production-grade workflow that consists of ancestry records and variety of the human genome to offer stepped forward variation calls and alignment,” says the organisation’s leader clinical officer, Brandi Davis-Dusenbery.

“The wish is that, with the aid of using accounting for that complexity withinside the evaluation, you’ll see stuff you have been missing,” says Bruce Gelb, the director of the Mindich Child Health and Development Institute on the Icahn School of Medicine at Mt. Sinai. “That’s been an concept floating round for some years, however no one previous to what Seven Bridges is doing carried out a graph-primarily based totally method this is practical. They’re the primary to do that.”

Gelb has been the usage of the GRAF platform to look for versions associated with congenital coronary heart defects and evaluating the ones versions to what turns up while he makes use of conventional series analyses. So a ways, he says, it seems that GRAF is figuring out a few versions that could in any other case were overlooked.

CRUICKSHANK-QUINN: “The truth that Seven Bridges GRAF is being made freely to be had to educational establishments will sincerely pave the way toward precision medication with the aid of using permitting studies development in under-represented populations with out the conflict of value to educational researchers.”



A important undertaking to handing over gene treatment plans to sufferers’ cells is the value of creating adeno-related virus (AAV), a not unusualplace vector for genes of hobby, says Ryan Cawood, CEO of UK-primarily based totally biotech organisation OXGENE. “The first AAV gene remedy product that became accredited withinside the EU value one million kilos in step with dose,” he says. “If you desired to deal with a disease [with a therapy targeting a large organ] that you may practice to lots of human beings, you simply honestly couldn’t make sufficient of it at a value that could make it viable.”

Currently, Cawood says, batches of cultured human cells are transfected with a couple of plasmids to result in them to make the AAV vectors containing a particular gene. But the plasmids are costly to make, and the transfection system isn’t very efficient. By assessment, contamination with adenoviruses clearly induces cells to spark off replication of AAVs. The hassle is, the adenoviruses additionally reflect themselves and contaminate the ensuing AAV product. To get round this trouble, OXGENE devised a genetic transfer that shuts down an adenovirus’s pastime midway thru its existence cycle inside a cellular, in order that it packages the cellular to churn out AAV debris however now no longer to make adenovirus. “When the virus is going in, you most effective get AAV coming out; you don’t get any greater of the adenovirus coming again out,” Cawood says. The organisation started promoting its studies-grade viral vector, which it calls TESSA, in September, and plans to start providing medical-grade cloth subsequent 12 months, he adds. The value for the studies-grade vector begins offevolved at £5,000, and relies upon on the dimensions of the batch of cells to be infected.

BLAINEY: “Supports translation of gene treatment plans. Demonstrates the biotechnical fee of organic engineering.”

Codex DNA BioXp 3250 System


Biotech company Codex DNA launched the BioXp™ 3250 system in August 2020 as a follow-as much as BioXp™ 3200, launched in 2014. The computerized platform for on-call for DNA meeting and amplification permits researchers to synthesize genes and genomes quicker than ever, with the capacity to boost up the improvement of vaccines, diagnostics, and remedies, says Peter Duncan, director of product control at Codex DNA. The system may be used on most cancers cells or quite a few infectious agents, inclusive of SARS-CoV-2.

Without BioXp™ 3250 or its predecessor, labs that need to synthesize DNA fragments, clones, or complete genomes ought to ship samples out to be processed with the aid of using a 3rd party. In addition to having to cope with transit, such processing ought to take weeks or months. With the BioXp™ 3250, priced at $100,000, DNA sequences as much as 7,000 base pairs in period may be assembled in a depend of days, with the frenzy of a button.

Rather than having to code genetic script on a laptop for unique experiments, clients can order a module that is available in approximately days, prepared to move. The module has a barcode containing all of the important records; while scanned with the aid of using the tool, commands for synthesizing the favored DNA are uploaded. A lab technician simply wishes to insert the module into the tool and press start, Duncan says.

“The BioXp has enabled us to carry out easy subcloning steps hands-loose,” Mark Tornetta, VP of Biologics Discovery at Tavotek Biotherapeutics, tells The Scientist in an email, describing how the lab makes use of the tool to generate NGS libraries. “All of those strategies [that are run] at the BioXP store us time and value to carry out.”

BLAINEY: “Democratizing gene synthesis with the aid of using putting functionality in character labs for quicker turnaround and decrease prices at excessive throughput.”

IsoPlexis Single-Cell Intracellular Proteome 


The Single-Cell Intracellular Proteome answer from IsoPlexis grew out of numerous labs at Caltech, all searching for higher approaches to screen protein-protein interactions
in most cancers cells with the aim of growing focused remedies. With conventional strategies inclusive of Western blot, mass spectrometry, and waft cytometry, most effective more than one protein sorts may be tracked at a given time. With Isoplexis’s system, released in July, researchers can screen 30 or greater protein pathways, with effects to be had at the equal day.

With preceding generation, phosphorylation became used to perceive the characteristic of the character proteins, and not using a perception as to how they paintings together. The Single-Cell Intracellular Proteome well-knownshows the characteristic the equal way, however is likewise capable of offer the context of complete protein signaling pathways, uncovering how the community operates as a complete.

Understanding the complete community of mobile pathways permits researchers to higher recognize the downstream outcomes of aberrant cells, says Sean Mackay, CEO and cofounder of IsoPlexis. In cancers, he adds, this method allows compare the efficacy of focused remedies inclusive of antibody treatment plans or small-molecule drugs.

“Such pathways essentially outline how cells are activated, [which] is specifically essential for most cancers, wherein activated phosphoprotein signaling isn’t most effective a trademark of most cancers,” says James Heath, who ran the Caltech lab that created the generation 8 years ago, “however is a main consciousness of focused inhibitors.”

MEAGHER: “The Single-Cell Intracellular Proteome answer makes use of modern microfluidics to diminish what seems like well-mounted ELISA chemistry right all the way down to the extent of unmarried cells.”

GigaGen Surge


Scientists have used intravenous immunoglobulin (IVIG) to deal with immunodeficient or immunosuppressed sufferers and convalescent plasma to deal with infectious sicknesses for greater than a century. And plasma is one in every of many remedies now being attempted for COVID-19. But organic samples drawn from donors aren’t the maximum standardized therapeutics. Enter GigaGen’s Surge platform, which makes use of unmarried-cellular sequencing to “seize and recreate” libraries of antibodies from blood donors. To create those libraries, the organisation runs donors’ blood samples thru the Surge platform to isolate character antibody-generating B cells into microdroplets and extract the RNA that encodes the antibodies. From those genetic sequences they are able to create a “blueprint of that person’s immune system,” says GigaGen CEO David Johnson.

Company researchers then choose a number of the ones antibodies to engineer in mammalian cells to create a recombinant antibody remedy, which they are saying is a good deal stronger than convalescent plasma or IVIG, primarily based totally on in vitro experiments and assessments in animal models. GigaGen does now no longer presently plan to promote Surge, however instead has been the usage of the platform to expand remedies for cancers, immunodeficiency disorders, and, maximum lately, COVID-19. GigaGen hopes to begin medical trials on their COVID-19 remedy, which makes use of greater than 12,500 antibodies from sixteen donors, in early 2021. The aim of Surge is to “tease aside the complexity of the immune system,” says Johnson, after which tailor antibody remedies that elicit the most powerful reaction.

Fred and Vicki Modell, who based the Jeffrey Modell Foundation after their son Jeffrey died at 15 because of headaches from number one immunodeficiency, say they were attempting to find an opportunity to IVIG, that’s occasionally in brief deliver and may cause facet outcomes in lots of sufferers. “[GigaGen] is giving the best present of all—they’re giving wish to [immunodeficient] sufferers,” Fred Modell says.

CRUICKSHANK-QUINN: “By combining unmarried-cellular emulsion droplet microfluidics generation, genomics, and protein library engineering, this antibody drug remedy, if successful, ought to revolutionize COVID-19 remedy in addition to remedies for lots exclusive sicknesses.”

10X Genomics Chromium Single Cell Multiome ATAC + Gene Expression


A few years ago, 10X Genomics released an assay, ATAC-seq, to perceive areas of open chromatin in unmarried cells; the product received a gap in The Scientist’s 2019 Top 10 Innovations. According to product advertising supervisor Laura DeMare, it wasn’t lengthy earlier than clients have been clamoring for greater, with remarks to the impact of, “‘This is great, however we’d sincerely like to get the gene expression records and the ATAC-seq records withinside the equal cellular.’” In September, 10X rolled out Chromium Single Cell ATAC + Gene Expression, which harvests each epigenetic and gene expression facts from character nuclei.

The platform tags mRNA and open chromatin fragments from every nucleus with DNA barcodes, DeMare explains, and the nucleic acids are then amplified and analyzed. “You can start to definitely hyperlink which regulatory factors withinside the genome are turning on or off genes,” she says. It prices approximately $2,four hundred in step with response for the reagents and a microfluidic chip.

Ansu Satpathy, an immunologist at Stanford University School of Medicine and a former postdoc of ATAC-seq codeveloper Howard Chang, tells The Scientist that he’s the usage of the brand new assay to analyze the outcomes of epigenetic adjustments related to T cellular exhaustion in tumor samples biopsied from most cancers sufferers. When exhausted, T cells come to be much less powerful at fighting most cancers, and “what we’re doing now with the RNA and ATAC approach mixed is asking, How do every of these molecular switches adjust genes that cause this dysfunctional final results withinside the cellular?” Satpathy says.

KAMDAR: “This method permits, for the primary time, the simultaneous profiling of the epigenome and transcriptome from the equal unmarried cellular, permitting a higher knowledge of cellular functionality.”

10X Genomics Visium Spatial Gene Expression Solution

A few years ago, 10X Genomics released an assay, ATAC-seq, to perceive areas of open chromatin in unmarried cells; the product received a gap in The Scientist’s 2019 Top 10 Innovations. According to product advertising supervisor Laura DeMare, it wasn’t lengthy earlier than clients have been clamoring for greater, with remarks to the impact of, “‘This is great, however we’d sincerely like to get the gene expression records and the ATAC-seq records withinside the equal cellular.’” In September, 10X rolled out Chromium Single Cell ATAC + Gene Expression, which harvests each epigenetic and gene expression facts from character nuclei.


The generation became evolved and initially advertised with the aid of using Swedish organisation Spatial Transcriptomics, which 10X Genomics received in 2018. Then 10X evolved the product in addition earlier than launching Visium ultimate 12 months. The Visium Spatial Gene Expression Solution, which sells for $1,000 in step with pattern, has smaller and greater densely packed spots—and 5 instances greater of them—than it did while the organisation inherited it, says Nikhil Rao, 10X Genomics’s director of strategic advertising for the spatial platform. This will increase decision, he explains. “We additionally stepped forward the sensitivity of the assay dramatically, being capable of select up tens of lots of precise molecular identifiers in step with spot.”

Rao says that lots of Visium’s customers consciousness on neuroscience, analyzing neurodegenerative sicknesses, for example. But the product is likewise being utilized in developmental biology, oncology, and immunology. Johns Hopkins University computational biologist Elana Fertig has used Visium to recognize how a most cancers can face up to remedy. “By distinctive feature of getting the spatial records of those cells, you may sincerely determine out the molecular mechanisms wherein they have interaction directly, due to the fact you may see if the cells are interacting physically,” she explains.

MEAGHER: “This is any other frontier in biology: now no longer simply unmarried-cellular or few-cellular gene expression, however now gathering gene expression facts with spatial decision at the extent of some cells.”

Inscripta, Inc. Onyx Digital Genome Engineering Platform


While CRISPR-primarily based totally genome modifying has come to be a extensively used method in labs everywhere in the globe, there are studies questions that require a scale of nucleotide tinkering that may be cumbersome, if now no longer prohibitive, for a few labs. Inscripta Inc.’s Onyx™ Digital Genome Engineering Platform gives a answer—absolutely computerized genome-engineered libraries with masses of lots of unmarried edits in microbial genomes. The benchtop tool, which released in October 2019 and sells for $347,000, permits customers to plant favored versions withinside the DNA of E. coli micro organism and S. cerevisiae yeast, and the tool looks after the rest.

The platform combines the whole thing from the algorithms for optimizing the modifying system to the microfluidics for coping with cells to the reagents themselves. “Biologists don’t ought to fear approximately the technical optimization anymore and may move in advance and consciousness on any hassle in biology now,” says Nandini Krishnamurthy, the vice chairman of packages improvement at Inscripta.

Shelley Copley, a molecular biologist on the University of Colorado Boulder, is an early tester of Onyx. She’s the usage of it to observe the outcomes of synonymous mutations, those who don’t extrade the ensuing protein, on health in E. coli. “The excessive-throughput a part of it’s far vital for you to deal with this,” she says. Rather than try and engineer every mutation she desires to observe one with the aid of using one, Onyx allows Copley to generate all 50,000 versions. Her crew can then circulate instantly to the health assays. “I don’t realize of every other generation which could do it.”

KAMDAR: “CRISPR is a effective device for modifying genomes and permitting purposeful checks which could elucidate causality and enhance our knowledge of genome biology. But the ones effects will now no longer be accomplished with out overcoming some of the technical and scalability challenges. This is what the Onyx Digital Genome Engineering Platform allows.”



John McLean, a bioanalytical chemist at Vanderbilt University, desires to realize precisely what’s in a gasp of fueloline, right all the way down to a vaporized blood or tissue pattern’s final lipid molecule. For years, he has used mass spectrometry to catalog compounds in a pattern with the aid of using weight. Sometimes exclusive molecules may have the equal mass and the equal atomic composition, making it difficult to differentiate them. Ion mobility separation runs fueloline samples down meter-lengthy tubes to distinguish molecules with the aid of using form and structure, getting across the mass trouble. But due to the fact the method became designed a long time ago, it hasn’t accomplished the equal decision as mass spectrometry. To attain a comparable decision, the ion separation tool could want a 13-meter tube.

Making a linear tube that period is impractical because of constraints on lab space. So some years ago, Richard Smith of Pacific Northwest National Laboratory and co-workers started brainstorming approaches to get ions to show corners. That dialogue brought about the improvement of MOBILion’s SLIM, or Structures for Lossless Ion Manipulation, an tool with a 13-meter tune reduce as switchbacks in circuit forums that match in a 3-meter-lengthy box; the tool offers facts on the dimensions and form of compounds in samples in minutes. SLIM “well-knownshows the unseen,” says Laura Maxon, MOBILion’s head of commercial enterprise improvement and company strategy, “with out the sacrifice of time.” This first generation of SLIM, which MOBILion started deploying as a Beta model to early adopter collaborators the second one sector of 2020, is constructed for scientists in a pharmaceutical or medical studies educational environment. The rate is aggressive with present technologies, she notes, and the organisation plans to layout the tool to be used withinside the health facility to perceive biomarkers of disease.

“What we’re seeing today, from MOBILion on SLIM, is simply the top of the iceberg,” McLean says. “There’s a whole lot of untapped capacity . . . from an analytical standpoint,” so “human beings ought to sincerely assume massive advances for those technologies.”

BLAINEY: “Ion-selective chromatography is important to biochemistry. Nice integration of microelectronic generation with biotechnology. ”


Paul Blainey

Associate professor of organic engineering at MIT and a middle member of the Broad Institute of MIT and Harvard University. The Blainey lab integrates new microfluidic, optical, molecular, and computational gear for utility in biology and medication. The organization emphasizes quantitative unmarried-cellular and unmarried-molecule methods, aiming to allow research that generate facts with the strength to show the workings of herbal and engineered organic structures throughout various scales. Blainey did now no longer do not forget merchandise submitted with the aid of using 10X Genomics in his ratings because of his monetary ties to the organisation.

Application scientist at Agilent Technologies.Previously, she became a postdoctoral fellow on the University of Colorado Denver – Anschutz Medical Campus, a studies fellow at National Jewish Health in Denver, and a graduate pupil on the State University of New York at Buffalo, wherein she labored withinside the tool center.

Kim Kamdar
Managing accomplice at Domain Associates, a healthcare-targeted mission fund developing and making an investment in biopharma, tool, and diagnostic groups. She started her profession as a scientist and pursued drug-discovery studies at Novartis/Syngenta for 9 years.

Robert Meagher

Principal member of Technical Staff at Sandia National Laboratories. His primary studies hobby is the improvement of novel strategies and gadgets for nucleic acid evaluation, specifically implemented to troubles in infectious disease, biodefense, and microbial communities. Most lately this has brought about methods for simplified molecular diagnostics for rising viral pathogens which might be appropriate to be used on the point-of-want or withinside the growing world. Meagher’s remarks constitute his expert opinion however do now no longer always constitute the perspectives of americaA Department of Energy or the US government.

Editor’s Note: The judges taken into consideration dozens of entries submitted for quite a few existence technological know-how merchandise with the aid of using groups and customers. The judging panel evaluated submissions with most effective primary commands from The Scientist, and its participants have been invited to take part primarily based totally on their familiarity with existence technological know-how gear and technologies. With the exception of Paul Blainey, who has monetary ties to 10X Genomics and consequently did now no longer do not forget that corporations merchandise in his ratings, they don’t have any monetary ties to the goods or groups concerned withinside the competition. In this trouble of The Scientist, any classified ads located with the aid of using winners named in this newsletter have been bought after our unbiased judges decided on the prevailing merchandise and had no bearing at the final results of the competition.

Corrections (December 1): The authentic model of this tale said that GigaGens Surge platform captured antibodies from samples that got here from plasma donors. They have been, in truth, blood donors. Changes have been additionally made to make clear the name of AbCellaras Maia Smith and the character of Celium and collaborations surrounding the device. The Scientist regrets those errors

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *